Latest Ratios: P/E Ratio -17.3x · EV/EBITDA N/A · ROE -29.1%. (2017–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $5.1B | $4.0B | $5.9B | $10.6B | $7.9B | $6.6B | $3.3B | — | — | — |
| Enterprise Value | $4.6B | $3.5B | $6.0B | $9.6B | $7.4B | $6.0B | $2.9B | — | — | — |
| P/E Ratio → | -17.30 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 4.98 | 3.89 | 9.49 | 37.16 | 67.86 | 95.39 | 44.36 | — | — | — |
| P/B Ratio | 5.09 | 4.00 | 5.72 | 8.47 | 10.67 | 8.57 | 5.57 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 3.42 | 9.59 | 33.83 | 63.57 | 87.16 | 38.33 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 60.3% | 60.3% | 62.6% | 49.4% | 44.1% | 100.0% | 100.0% | 100.0% | 100.0% | 100.4% |
| Operating Margin | -13.3% | -13.3% | -48.3% | -154.1% | -389.4% | -570.0% | — | -214.4% | -3.1% | 58.4% |
| Net Profit Margin | -28.8% | -28.8% | -28.2% | -181.8% | -381.5% | -586.4% | -355.2% | -164.4% | -5.7% | 39.7% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -29.1% | -29.1% | -15.4% | -51.9% | -59.1% | -59.2% | -112.2% | — | -26.7% | 77.0% |
| ROA | -17.4% | -17.4% | -10.1% | -32.6% | -36.4% | -43.8% | -52.8% | -28.3% | -0.8% | 3.9% |
| ROIC | -12.7% | -12.7% | -32.3% | -120.9% | -154.3% | -170.4% | — | — | — | 100.2% |
| ROCE | -11.0% | -11.0% | -20.1% | -33.0% | -47.4% | -52.4% | — | -61.7% | -0.7% | 7.4% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.41 | 0.41 | 0.34 | 0.26 | 0.38 | 0.16 | 0.01 | — | 0.50 | 0.02 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | 28.97 | 0.02 |
| Net Debt / Equity | — | -0.49 | 0.06 | -0.76 | -0.67 | -0.74 | -0.76 | — | -23.80 | -0.15 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | -1381.54 | -0.13 |
| Debt / FCF | — | — | — | — | — | — | — | — | -0.72 | — |
| Interest Coverage | -12.21 | -12.21 | -6.32 | -22.87 | -40.29 | -451.44 | -73.20 | -594.23 | -18.71 | — |
Net cash position: cash ($902M) exceeds total debt ($414M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.96 | 1.96 | 4.62 | 6.92 | 3.69 | 4.14 | 5.14 | 1.62 | 2.05 | 4.43 |
| Quick Ratio | 1.91 | 1.91 | 4.54 | 6.83 | 3.66 | 4.14 | 5.12 | 1.61 | 2.05 | 4.43 |
| Cash Ratio | 1.49 | 1.49 | 4.04 | 6.05 | 3.44 | 3.85 | 4.38 | 1.25 | 1.36 | 0.04 |
| Asset Turnover | — | 0.59 | 0.38 | 0.15 | 0.09 | 0.06 | 0.10 | 0.21 | 0.11 | 0.10 |
| Inventory Turnover | 12.75 | 12.75 | 9.81 | 7.42 | 6.31 | — | — | — | — | -8.73 |
| Days Sales Outstanding | — | 88.79 | 72.67 | 201.05 | 138.87 | 310.49 | 402.06 | 211.19 | 806.53 | 3538.66 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $184M | $183M | $176M | $159M | $141M | $118M | $132M | $100M | $132M |
Concentrated Single Asset Dependency
As reported in recent financial filings, Legend Biotech trades at a price-to-sales ratio of 5.16, a valuation that appears to price in significant future market share gains for its lead CAR-T therapy relative to the broader biotechnology sector's historical trading multiples.
The forward P/E of 492.11 suggests that the market is heavily discounting near-term losses in favor of long-term terminal value, assuming successful label expansion into earlier lines of therapy. Investors should monitor whether this premium remains sustainable if the company fails to demonstrate a clear path to operating profitability within the next several quarters.
Based on the company's reported figures, the ROIC of -6.1% in 2026Q1 highlights the ongoing struggle to generate positive returns on invested capital while the firm continues to sink substantial resources into its specialized manufacturing infrastructure and commercial launch efforts.
The persistent negative ROIC trend over the last ten quarters suggests that the company is currently in a capital-intensive phase where the cost of building out the vein-to-vein supply chain outweighs the immediate returns from product sales. This warrants further investigation into whether future manufacturing efficiencies can eventually drive returns above the company's cost of capital.
According to recent quarterly data, the cash conversion cycle has fluctuated significantly, reaching 42 days in 2026Q1, which suggests that the company's working capital management is heavily influenced by the timing of inventory build-ups and the settlement of receivables within the J&J partnership.
The asset turnover ratio of 0.18 remains low compared to broader industrial peers, reflecting the high capital base required to support a single-asset commercial model. Investors should monitor whether the company can improve its inventory turnover as it scales, as current levels indicate potential inefficiencies in managing the complex logistics of autologous cell therapy.
As indicated by the 2026Q1 balance sheet, the company maintains a current ratio of 2.13, providing a sufficient liquidity buffer to navigate the ongoing cash burn associated with its complex manufacturing and commercialization requirements for the foreseeable future.
The quick ratio of 2.05 suggests that the company is not overly dependent on inventory liquidation to meet its short-term obligations, which is a positive sign given the specialized nature of its products. However, the reliance on external capital remains a risk factor that could impact liquidity if market conditions for biotech financing tighten.
The price-to-earnings ratio is frequently misapplied to Legend Biotech, as the company's current negative earnings and heavy reliance on milestone-driven collaboration revenue render traditional P/E metrics largely meaningless for assessing the underlying commercial health of the business.
Investors should instead focus on net trade sales and the progression of operating margins, as these metrics better reflect the true unit economics of the CAR-T business. Relying on P/E ratios obscures the significant impact of non-recurring milestone payments and the high variable costs inherent in the current manufacturing model.
Includes 30+ ratios · 9 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying LEGN stock.
Legend Biotech Corporation's current P/E ratio is -17.3x. This places it at the 50th percentile of its historical range.
Legend Biotech Corporation's return on equity (ROE) is -29.1%. The historical average is -34.6%.
Based on historical data, Legend Biotech Corporation is trading at a P/E of -17.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Legend Biotech Corporation has 60.3% gross margin and -13.3% operating margin.